Genelux Corp. (GNLX) is nearing a period of heightened significance in its clinical progress, with two key data readouts expected in the second half of 2025 that could reshape its development arc.
The company's proprietary oncolytic immunotherapy, Olvi-Vec, is being evaluated across multiple indications, and upcoming results may determine the viability of its systemic delivery strategy and broader therapeutic potential.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.